glp 1 and substance use disorder disorders (SUDs) may become the next therapeutic target for GLP-1 receptor agonists (GLP-1s). Although the evidence remains preliminary, growing preclinical, observational, early clinical data suggest these drugs may reduce Frontiers | Association between GLP-1

Optimized L-Carnitine

PubMed research supports that insulin resistance is a core factor in various health issues beyond diabetes, including fatty liver, cognitive impairment, and cardiovascular disease (Springer)

Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study

Currently, targeting the NLRP3 inflammasome pathway or directly neutralizing IL-1 (e.g., Canakinumab) is considered a highly promising frontier for treating refractory gout and preventing gout flares [2]

Nausea, vomiting, dyspepsia and diarrhea are common side effects

You should address any concerns about premature grays or hair loss with a doctor.